Upgrade to SI Premium - Free Trial

H.C. Wainwright Reiterates Buy Rating on Relmada Therapeutics Inc (RLMD)

June 23, 2026 6:50 AM
H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $12.00 price target on Relmada Therapeutics Inc (NASDAQ: RLMD).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments